The Expanding Role of the Pharmacist in HIV Prevention

Faculty

Richard A. Elion, MD
Associate Clinical Professor of Medicine
George Washington University School of Medicine
Director, Clinical Research
Whitman-Walker Health
Washington, DC

James D. Scott, BS, MEd, PharmD
Associate Dean
Experiential and Professional Affairs
Professor, Pharmacy Practice and Administration
Western University of Health Sciences
Pomona, California

Elyse Tung, PharmD, BCACP
Clinical Assistant Professor
University of Washington School of Pharmacy
Director of Clinical Services
Kelley-Ross Pharmacy at the Polyclinic
Seattle, Washington

Course Description

The most recent estimates from the Centers for Disease Control and Prevention (CDC) state that approximately 37,000 people in the United States become infected with HIV each year.¹ To reduce the number of new infections, health care providers should be prepared to discuss the potential benefits of preexposure prophylaxis (PrEP) with adults who are at particularly high risk for acquiring HIV.² The United States Public Health Service (USPHS) and the CDC have published clinical practice guidelines on identifying candidates and prescribing medication approved by the US Food and Drug Administration (FDA) for HIV PrEP.³ During this Interactive Exchange™ program, expert faculty will review these guidelines with a focus on how pharmacists can facilitate patient engagement and retention in HIV-prevention services.⁴ Key topics will include recommendations on universal HIV testing, cohorts at substantial risk for HIV acquisition, criteria for PrEP eligibility, and practical approaches to monitoring PrEP outcomes and adherence.¹ Faculty will also discuss the growing evidence pool supporting pharmacy-based programs to highlight opportunities for program attendees to play increasingly central roles in the prevention of new HIV infections.⁵

References

1. CDC. CDC fact sheet: HIV incidence: estimated annual infections in the U.S., 2008-2014. Overall and by transmission route. <https://www.cdc.gov/nchhstp/newsroom/docs/factsheets/hiv-incidence-fact-sheet_508.pdf. Updated February 2017>. Accessed October 31, 2017. 
2. Truvada (emtricitabine/tenofovir disoproxil fumarate) [prescribing information]. Initial US approval 2004. Foster City, CA: Gilead Sciences, Inc; 2017.
3. CDC. USPHS Preexposure Prophylaxis for the Prevention of HIV Infection in the United States—2014. https://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf. Accessed October 31, 2017.
4. CDC. Effectiveness of Prevention Strategies to Reduce the Risk of Acquiring or Transmitting HIV. https://www.cdc.gov/hiv/risk/estimates/preventionstrategies.html. Updated March 2017. Accessed October 31, 2017. 
5. CDC. Innovative CDC effort expands HIV testing into pharmacies. http://www.cdc.gov/nchhstp/newsroom/2012/nhtdpressrelease2012.html. Published June 2012. Accessed October 31, 2017.

Target Audience

This activity has been designed to meet the educational needs of pharmacists engaged in the care of patients at risk for HIV.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

• Provide proactive, universal HIV-risk screening, identify patients at substantial risk for HIV acquisition, and determine PrEP eligibility
• Create open patient-provider dialogue and engage the patient as an active, educated participant in clinical decision-making, ongoing patient-centric monitoring, and comprehensive risk-reduction strategies
• Counsel patients regarding PrEP efficacy, safety, and optimal use, and offer treatment-adherence counseling to patients receiving PrEP
• Provide ongoing guideline-based clinical and laboratory monitoring for patients receiving PrEP

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. 

Richard A. Elion, MD: Consultanting fees: Gilead Sciences, Inc.; ViiV Healthcare; Fees for non-CME/CE services: Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Contracted research: Gilead Sciences, Inc.

James D. Scott, BS, MEd, PharmD: Has nothing to disclose.

Elyse Tung, PharmD, BCACP: Honoraria: Gilead Sciences, Inc.; Fees for non-CME/CE services: Gilead Sciences, Inc.

Non-faculty

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose. The Integritas Communications planners and managers, Jim Kappler, PhD, and Jeanette Ruby, MD have nothing to disclose.

Financial Support

This activity has been supported by an independent educational grant from Gilead Sciences, Inc.

Provider Information

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Pharmacy Education 

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. 

(Universal Activity Number - 0809-9999-18-307-H02-P)

Type of Activity: Application  

CME Inquiries/Special Needs

For questions regarding the accreditation of this program, please contact Postgraduate Institute for Medicine (PIM) at www.pimed.com.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation and Request for Credit

There are no fees for participating and receiving credit for this activity. During the period March 5, 2018 through March 5, 2019, participants must read the learning objectives and faculty disclosures and study the educational activity.

Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.